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INTRODUCTION 
 Smoking is a major addiction in this era and even with widespread 
criticism, its use is on the rise. Smoking dates back to 5000 BC and it has taken 
many forms. As civilization evolves in many parts of the world the form of 
smoking gets a various shape. Currently, the major form of smoking is cigarette 
smoking with tobacco as its content. Ill effects of smoking have been 
publicized widely for the last 60 -70 years by governments all over the world. 
These steps have prevented a surge in tobacco smoking but nevertheless to say 
its use is on a plateau with many youngsters at risk to its use. Growing urban 
settlements, peer pressure, and rising social miscreants are some of the causes 
targeting the younger generation to lure them into various addictions with 
cigarette smoking as the initial step. Cigarettes are easily available than other 
substance abuse products. Hence cigarette smoking in the long-term has caused 
a major burden on the economy globally. Health-related issues are on raise. 
Cigarette smoking has been one of the attributes to a large number of 
respiratory ailments and cancer.  
 There is no respiratory pathology without cigarette smoking as its cause. 
That’s the nature of its ill effects caused by cigarette smoking. A multitude of 
cancer has its etiology or a trigger as smoking. Many non-communicable 
diseases like hypertension, reproductive diseases among men and women have 
been linked to smoking. Various Governments and health agencies are crying 
out to the public to curb its use in ways it may reach a large section of the 
population. Our Indian government and various state administrations have 
taken various actions. Ban commercial advertisements for cigarettes, portray 
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the oncogenic and respiratory ailments on packets and to limit the use of 
cigarette smoking by actors on Television and movie platforms with statutory 
warnings. The ban on non-smokable tobacco has made cigarette as a sole 
recreational product available to people with its addiction. Hence, cigarette 
smoking is something that is hugely popular, and its containment is very 
difficult among the general public. We are trying to bring the ill-effects of 
cigarettes at a prevention level.  
 In this study, we have elaborated its ill effects by comparing to non-
smokers.Chronic obstructive pulmonary disease (COPD) is one such 
respiratory ailment which is on rising to cause mortality and morbidity and 
resulting in a huge burden on the health care system and economic productivity 
socially 1. COPD is an anatomical damage caused to lungs by the direct effects 
of smoking.COPD on a larger scale has no connections with genetic and other 
individual parameters among smokers. It depends on the number of cigarettes 
smoked per day and years with smoking history.  
 More the exposure to harmful toxins more the damage to the fragile lung 
parenchyma and its conduits. An obstructive pattern can be identified early 
with Pulmonary function tests. One such parameter is Mid-expiratory flow rate 
(MEFR) which identifies the obstruction of the smaller airways like 
bronchioles at earliest2. Importance of this particular parameter lies its ability to 
detect the obstruction of airways which can be reversed with complete 
abstinence from smoking. We take asymptomatic smokers and comparable 
non-smokers into the study and analyze the MEFR.  
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AIMS AND OBJECTIVES 
  The aims and objectives of my study includes: 
1. To study the influence of smoking on pulmonary functions 
2.  To study the differences in Mid Expiratory Flow Rate values in 
smokers and non-smokers and their variation. 
3. To study the ventilatory impairment caused by smoking in terms 
of obstructive, restrictive or mixed type. 
4. To establish normal standards in healthy non-smoker adults. 
5. To use pulmonary function test as a tool to identify the quantum 
of damage to the respiratory tree. 
6. To create awareness about the ill effects of smoking. 
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REVIEW OF LITERATURE 
Smoking: 
 Cigarette smoking referred to just smoking in this work is the major 
preventable cause of non-communicable ailments which impair the economic 
productivity and health of major economies around the world. More alarming is 
the rising trend in smoking among the adolescents and its worrying spread 
within communities in the developing world 3. Smoking is an important risk 
factor for Non-communicable diseases. Total burden of NCD is expected rise 
from 40% in 1990 to 75% in 2030 11. Analyzing the reliable predictors of 
smoking onset help in developing effective programs in preventing smoking. 
These parameters include socioeconomic status, peer pressure, knowledge in-
terms of literacy, attitude, family background, and support. Smoking onset 
involves various factors and its maintenance ranges from trying, experimenting 
and a regular smoker. Lower socioeconomic status, single parent, school, and 
the area where it is located, money availability are some of the factors luring 
adults into smoking. 
 Social bonding which includes family bonding, peer bonding, school 
influences, and religion. Family bonding in terms of attachment to father/ 
mother, level of supervision, strictness is considered. Single parent status and 
inappropriate emotional connect with teens are major risk factors in the ignition 
of smoking. Family smoking in terms of father/sibling smoking has good 
predictive value. Of more important was sibling smoking habit which has 
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 In the 1980s tobacco deaths were around 630000 per year 5. Current 
estimates have increased to 800000 to 900000 per year and there are no signs 
of decline. Among the attributes, an alarming one is the incidence of oral 
cancers among men and women. Easy availability of different smoking and 
non-smoking forms of tobacco lead to cancers especially mouth cancer. Heart-
related ailments in people less than 40 years is contributed by smoking. Every 
year 4.5 million smokers in India suffer from heart ailments and 3.9 million 
people from respiratory diseases. Noteworthy is that these morbidities are 
completely preventable. World Health Organization (WHO) predicts the 
number of deaths related to smoking may increase to 1.5 million by 2020 6. In a 
study conducted by Gupta et al shows around 23.7% of the deaths among men 
and 23.7% of the deaths among women in the economically productive age 
group are due to tobacco-related illness 7. 
 In our country NFHS -3 surveys (National Family Health Survey - 3) 
conveyed that smoking is more prevalent among men, rural population, the 
illiterate, poor and vulnerable section of the society 8.In India’s smoking 
pattern is a complex problem as there are many products and its cultural beliefs 
give rise to many deep-rooted menaces in bringing down its use. People smoke 
beedis which are manufactured at cottage-based enterprises and cigarettes from 
multinational companies. Beedis are largely consumed than cigars,12 especially 
among the rural population and low socioeconomic state people. According to 
Pednekar et al.  beedi smokers have a higher incidence of oral cancers than 
cigarette smokers 11.  India is a low and middle-income country; LMIC.With its 
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 Due to the globalization of the tobacco epidemic WHO framework 
convention on tobacco control (WHO FCTC) was formed with the aim of 
reducing the burden of the disease. It was adopted in May 2003 and India was 
the eight country to pursue its ideas. Various guidelines were proposed to 
encourage smokers to quit smoking and more importantly restrain non-smokers 
from taking up such habits. Global political will for tobacco control is 
appreciated by the fact that more than 86% of the world’s population is under 
the FCTC guidelines. This makes WHO FCTC more comprehensive and 
successful. 
 Since 1975, there is a mandatory display of a statutory warning on the 
cigarette and other tobacco products. Through Cigarettes and other tobacco 
products Act (COTPA) certain rules were formulated and it was reinforced 
from 1 May 2004. 
The key provisions of COTPA -2003 12 are as follows: 
• Prohibition of smoking in public places (including indoor 
workplaces). Its implementation starts from 2nd October 2008. 
• Prohibition of advertisement, direct and indirect (point-of-sale 
advertising is permitted), sponsorship and promotion of tobacco 
products. 
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• Prohibition of sales to minors (tobacco products cannot be sold to 
children less than 18 years of age and cannot be sold within a radius 
of 100 yards of any educational institutions). 
• Regulation of health warning in tobacco products packs. Health 
warnings are typed in English and in the local Indian language. 
Pictorial health warnings also to be included. 
• Regulation and testing of tar and nicotine contents of tobacco 
products and declaring on tobacco products packages. 
National Tobacco Control Programme (NTCP): 
 The government of India (GOI)through Ministry of Health and Family 
Welfare (MHFW) launched NTCP in the eleventh 5-year plan to bring about 
greater awareness at local levels and to involve grass root workers in health 
care settings for tobacco control. It strengthens the WHO-FCTC guidelines. It 
was approved by the Cabinet Committee on Economic Affairs (CCEA) on 28 
 January 20
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Global adult Tobacco survey -2 (GATS-2) Fact sheet INDIA 2016-2017: 
 It is a household survey of persons aged 15 and above conducted in all 
states and union territories. The first round was conducted in 2009-10 14. The 
second round in 2016-17 by Tata Institute of social sciences, Mumbai. A total 
of 74,037 individuals were interviewed from August 2016 to February 2017. 
 Objectives of GATS is to systematically monitor adult tobacco use and 
track key tobacco control indicators. It helps countries like India to fulfill their 
obligations under the WHO FCTC and to generate data within and across 
countries. 
Key findings in GATS 2 include the following: 
• Prevalence of tobacco use has been decreased by 6 percentage from 
34.6% in GATS-1 in 2009-10 to 28.6% in 2016-17. 
• 19.0% of men, 2.0% of women and 10.7% of all adults’ smoke 
tobacco. 
• Khaini and bidi are the most commonly used products.11% use 
khaini and 8% use bidi. 
• Prevalence of tobacco use among minors aged 15-17 has been 
decreased from 10% in GATS-1 to 4% in GATS-2. 
• 55% of smokers are planning or thinking to quit smoking.49 % of 
smokers were advised by health care providers to quit tobacco. 
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111,363 individuals were identified from 32945 households.99825 individuals 
completed the requisite process in the interview. The overall Household 
response rate was 89.24%. GATS questionnaire was translated into Tamil.31 
educational institutes and 3 NGO’s participated in the survey. 
Things that were assessed include: 
• Prevalence of tobacco use 
• Exposure to second-hand smoke 
• Cessation of smoking 
• Impact of tobacco control measures. 
• Prevention initiatives in TamilNadu 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18
 
19
Regarding tobacco use: 
1. An estimated 28, 64, 400 people aged 15 years & above in Tamil 
Nadu, use tobacco in any form.  
2. The overall prevalence of tobacco use in Tamil Nadu was 5.2%. 
3. Tobacco use among males was higher (4.3%) compared to females 
(0.9%). 
4. Smoking tobacco-3.3% (Cigarette users - 1.7%, Bidi users - 1.4%) 
Smokeless tobacco - 2.1%. 
5. The highest prevalence rate was observed in Pudukkottai District 
(19.9%) and the lowest was in Thanjavur district (1.2%). 
6. No differences in tobacco use between urban (2.5%) and rural areas 
(2.6%) of Tamil Nadu. 
7. Tobacco use prevalence had come down from 16% in the year 2009-
2010 (Global Adult Tobacco Survey: 2009-2010) to 5.2% in the year 
2015-2016 in Tamil Nadu.  
8. Average age at initiation of tobacco use was 24.7 years; 25.7% of the 
respondents initiated the use before the age of 18 years. 
9. 47% of current tobacco users consumed tobacco within half an hour of 
waking up. 
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Cessation: 
1. 54% of the current users were concerned about their tobacco use  
2. 17.2% of the current users reported that they were thinking of quitting 
in the next one month 
3. 38.9% of the current users had tried to quit tobacco in the last 12 
months Cessation methodologies used were counseling (14.3%), NRT 
& Medication (3.4%), Self-attempt (7.1%) 
4. 34.9% current users were asked for their tobacco use by a healthcare 
provider in the last 12 months  
5. 37.7% of the current users were advised by a health care provider to 
quit tobacco 
Pictorial warnings: 
 Survey were conducted regarding pictorial warning and its impact on 
smoking cessation: 
1. 67.3% of the current tobacco users noticed pictorial warning on the tobacco 
products they used, in the last one month.  
     Smokers-63.6%, (Cigarettes-38.5%, Bidi-25.2%), Smokeless tobacco users-
32%, Dual users-4.3%  
 
2. Of the current tobacco users who noticed pictorial warning, 61.3% were 
motivated to quit.       
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   Smokers-64.2%, (Cigarettes-37.4%, Bidi-26.8%), Smokeless tobacco users-
29.7%, Dual users-3.6% 
 
Smoke free Policies at home and work place: 
1. 96.6% of the respondents reported that smoking is not permitted at their 
home, however 15% of the houses had people smoking at home, daily. 
2. 15.7% of the respondents reported that their workplace did not have any 
smoke free policy and in 5.7% of the workplaces, smoking was allowed 
everywhere. 
Role of Media: 
1. Respondents who noticed anti-tobacco messages in the last one month: 
91.9% Television - 7 7. 1 %,Newspaper - 1 4. 6 %, Films-23.3%,  
Theatre - 16%  
2. 78.4% of the respondents noticed tobacco advertisement or promotional 
messages in the last one month. Television 12.2 %, News Paper 2.9 %, 
Films 3.4 %, Theater 2.7% 
 
Knowledge Attitude and Perception: 
1. 95% of the respondents were aware that tobacco causes serious illness.  
2. 70.6% of the respondents believed exposure to tobacco smoke causes 
serious illness among non-smokers.  
3. Respondents attributed tobacco use with Cancer - 80%, Heart attack – 
33.5%, Infertility- 4.6%. 
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Smoking and nicotine:  
 Nicotine is the primary compound responsible for the ill effects of 
smoking. It is involved in psychological and pharmacological mechanisms 
responsible for addiction and maintenance. It activates the dopaminergic 
system15,16 in the mesolimbic pathway and it is responsible for the withdrawal 
effects of smoking cessation. Nicotine acts at neuronal acetylcholine receptors 
throughout the central nervous system and at the level of postsynaptic junction 
in the autonomic nervous system.  
 A gradual increase in these receptors with daily nicotine use explains its 
tolerance. Hence, smokers of cigarettes increase the smoking rate, intensity to 
maintain the nicotine levels in plasma17. Studies show smokers extract around 
1-2 mg of nicotine per cigarette whereas the amount measured by smoking 
machines using human parameters is around 2-3 mg per cigarette. This shows 
smokers absorb half of the nicotine inhaled 18. It is the peak concentration of 
nicotine in the brain which is responsible for reward, tolerance and addiction 
principle. It is absorbed in seconds throughout the body with the initial dosing.  
 Half-life is 2-3 hours and it is metabolized to cotinine by cytochrome 
P450 2A6.P 450 2A6 is also responsible for potent activation of carcinogen 
NNK. Clearance of nicotine is typically diurnal with midday peak and spikes of 
increased clearance after a meal. This explains increased smoking in the early 
morning, lowest in the evenings and increased smoking rate after meals 19. 
There is inter-individual variation in the nicotine and cotinine metabolism 
addressed by varying clearance of cotinine and its effect on consumption and 
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dependence. The number of cigarettes smoked per day can be assessed by the 
plasma and urinary nicotine and cotinine concentration. Cotinine has a half-life 
greater than nicotine and hence used a useful biomarker in terms of smoking 
surveys, smoking cessation trials, and the assessment of exposure to 
environmental cigarette smoke. Studies done by Carabello RS et al. and Perez-
stable et al. showed inter-individual variation in nicotine metabolism. They 
proved that nicotine intake per cigarette is significantly higher among African- 
Americans than Caucasian-American smokers 20,21.  
Carcinogen in cigarette smoke: 
 An overview of the carcinogenic effect of smoking will further add to 
the need for this comparative study between smokers and non-smokers. A 
multitude of carcinogens plays a role in the development of oral and lung 
cancer. Apart from nicotine, there are small doses of polycyclic hydrocarbons 
(PAH) and NNK which are lung carcinogens on metabolic activation. There are 
competing detoxification pathways which differ among ethnic groups and 
hence differ in carcinogenic potential among individuals. Metabolic activation 
leads to the formation of DNA adducts which cause mutation. DNA adducts 
may escape DNA repair mechanisms and their existence lead to activation of 
oncogene or impairment of Tumor suppressor gene. There is also a mutation of 
human KRAS and p53 gene in smoker leading to lung cancers. 
 Summary
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inspiratory and maximal expiratory pressure are a simple and convenient way 
to measure the respiratory muscle strength. Cigarettes smoking causes a deficit 
in both the FEV1/FVC and MEF 25-75% suggesting it causes airway 
obstruction and small airway disease. 
 A study conducted by Tantisuwat36 et al showed the effects of smoking 
on chest expansion, lung function and respiratory muscle among young people. 
Questions related to smoking and nicotine dependence through Fagerstrom test 
for nicotine dependence questionnaire. 
 Fagerstrom test assesses the intensity of physical dependence on 
nicotine. It evaluates the number of cigarettes smoked, its addiction propensity 
and its dependence. 
 The items include Yes/No questions which are marked from 0 to 1and 
the multiple-choice questions are graded from 0 to 3. The sum is 10 at the end 
of the test and its interpretation is validated. The higher the score, more intense 
is the physical dependence on nicotine. This was developed by Karl-Olov 
Fagerstrom and modified by Todd Heatherton 33,34 in 1991. This test is now 
copyrighted by Taylor and Francis Ltd. and can be reproduced without 
permission. 
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Fagerstrom Test for Nicotine dependence: 
 Please  Tick One box for each 
question  
Score 
how soon after waking do 
you smoke your first 
cigarette ? 
Within 5 minutes 
5-30 minutes 
31-60 minutes 
3 
2 
1 
Do you find it difficult to 
refrain from smoking in 
places where it is forbidden?
Church, library, etc. 
 
YES  
NO 
1 
0 
Which cigarette you hate to 
give up? 
The first in the morning 
Any other 
1 
0 
How many cigarettes a day 
you smoke ? 
 
10 or less 
11-20 
21-30 
31 or more 
0 
1 
2 
3 
Do you smoke frequently in 
the morning ? 
YES  
NO 
1 
0 
Do you smoke even if you 
are sick in the bed most of 
the day? 
YES  
NO 
1 
0 
 Total Score   
 
Score: 
1-2 = low dependence                      3-4 = low to moderate dependence 
5-7 = moderate dependence             8+ = high dependence 
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Scoring of Fagerstrom Test for Nicotine dependence: 
• Score of 1-2 
 A patient who scores between 1 and 2 on the Fagerstrom Test for 
Nicotine dependence is classified to have a low dependence- Suggests they 
may need nicotine replacement therapy but should be monitored for withdrawal 
symptoms. 
• Score of 3-4 
 A patient who scores between 3 or 4 on the Fagerstrom Test for 
Nicotine dependence is classified to have a Low to moderate dependence- 
Should be offered patches, inhaler, lozenges or gums. 
• Sore of 5-7  
 A patient who scores between 5 to 7 on the Fagerstrom Test for Nicotine 
dependence is classified to have a moderate dependence on nicotine- offered 
patches, inhaler, lozengesorgums. Should also offered combination therapy of 
patches with lozenge and gum. 
• Score of 8 and over 
 A patient who scores between 5 to 7 on the Fagerstrom Test for Nicotine 
dependence is classified to have a Higher dependence on nicotine. Should be 
offered combination therapy of patches with lozenge and gum. 
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Nicotine recommendations chart: 
Dependence level Nicotine replacement 
therapy dosage 
Combination therapy 
HIGH Patches: 21mg/24hr or 
15mg/16hr  
Inhaler: 6 –12 cartridges 
per day  
Lozenge: 4mg  
Gum: 4mg  
Patches: 21mg/24hr or  
15mg/16hr 
AND  
Lozenge or Gum: 2mg  
MODERATE Patches: 21mg/24hr or 
15mg/16hr  
Inhaler: 6 –12 cartridges 
per day  
Lozenge: 4mg  
Gum: 4mg 
Patches: 21mg/24hr or 
15mg/16 hr AND  
Lozenge or Gum: 2mg 
LOW TO MODERATE Patches: 14mg/24hr 
patch or 10mg/16hr  
Inhaler: 6 –12 cartridges 
per day  
Lozenge: 2mg  
Gum: 2mg  
Patches: 14mg/24hr or 
15mg/16hr  
AND  
Lozenge or Gum: 2mg  
LOW May not need NRT 
Monitor for withdrawal 
symptoms  
Patches: 7mg/24hr patch 
or 5mg/16hr  
Lozenge: 2mg  
Gum: 2mg 
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‘FOUR Cs’ Test 
 DSM IV has laid down criteria in terms of 4C ’s which are conveniently 
labeled as Compulsion, control, cutting down, and consequences. 
1. Compulsion  -  The intensity with which the desire to use a chemical 
overwhelms the patient's thoughts, feelings, and 
judgment. 
2. Control - The degree to which patients can (or cannot) control 
their chemical use once they have started using. 
3. Cutting down - The effects of reducing chemical intake; withdrawal 
symptoms. 
4. Consequences - Denial or acceptance of the damage caused by the 
chemical. 
TO assess these parameters physicians approach the 
patients in terms of questions.  Assessing Nicotine 
Addiction Using the “Four Cs” Test 
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Compulsion 
• Do you ever smoke more that you intend? 
• Have you ever neglected a responsibility because you were smoking, or so 
you could smoke? 
Control 
• Have you felt the need to control how much you smoke but were unable to 
do so easily? 
• Have you ever promised that you would quit smoking and bought a pack of 
cigarettes that same day? 
Cutting down (and withdrawal symptoms) 
• Have you ever tried to stop smoking? How many times? For how long? 
• Have you ever had any of the following symptoms when you went for a 
while without a cigarette: agitation, difficulty concentrating, irritability, 
mood swings? If so, did the symptom go away after you smoked a 
cigarette? 
Consequences 
• How long have you known that smoking was hurting your body? 
• If you continue to smoke, how long do you expect to live? If you were able 
to quit smoking today and never start again, how long do you think you 
might live? 
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Many assessments have come out in a prolific way to set standards into 
smokers’ profile; which available for patient’s use. 
Smoker's Profile35: 
Stress relief 
• When you're frustrated or angry, do you automatically think about smoking 
a cigarette? 
• If you're upset or scared, does a cigarette help you calm down? 
• Do you rely on cigarettes when you're under stress? 
• Recall a time when you stopped smoking for a while. After you stopped 
smoking, did you want a cigarette more whenever you got upset or angry? 
Did you miss cigarettes more when you were under a lot of stress or 
tension? 
Conditioned responses 
• How often do you smoke while you're driving a car or drinking a cup of 
coffee? 
• If you're with someone who's smoking, do you automatically smoke, too? 
• Do you usually smoke a cigarette during or after a meal? 
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• Recall a time when you stopped smoking for a while. Did being around 
smokers make it hard to not smoke? Were there certain people, places or 
things that made you want to smoke? 
Relief of withdrawal symptoms 
• When do you smoke your first cigarette of the day? 
• Do you get irritable if you have to go more than two hours without a 
cigarette? 
• Do you have trouble concentrating if you're not smoking? 
• Recall a time when you stopped smoking for a while. Did you get irritable 
or moody during the first few days after you stopped? Did you have trouble 
concentrating during the first few days after you stopped? 
Elevation of depressed mood 
• Recall a time when you stopped smoking for a while. Did you become 
more depressed? 
• When you woke up in the morning, did you feel that you could spend all 
day in bed? 
• How was your energy level after you stopped smoking? 
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 After assessing the Smoker’s profile need to assess the readiness to 
change. Mere question of ‘Do you smoke?’ gathers information about smoking 
but not the cognitive aspect of smoking. This continuum of change in smoking 
pattern can be staged into Precontemplation, contemplation, preparation, 
action, maintenance and relapse. 
Summary of Physician Counselling Based on the Stages of Change 
STAGE OF 
READINESS 
PATIENT 
RESPONSE TO: 
“WHAT ARE YOUR 
THOUGHTS AND 
FEELINGS ABOUT 
QUITTING 
SMOKING?"
GOAL OF 
INTERVENTION 
TYPICAL 
PHYSICIAN 
INTERVENTION 
Precontemplation “I like to smoke.” Introduce 
ambivalence 
“Your emphysema 
will improve after 
you've quit 
smoking.” 
Contemplation “I like to smoke, 
but I know I need 
to quit.” 
Resolve 
ambivalence 
“How will your 
life be better after 
you've quit 
smoking?” 
Preparation “I'm ready to 
quit.” 
Identify successful 
strategies 
“Choose a ‘quit 
day’ and let's make 
plans for it.” 
Action “I'm not smoking, 
but I still think 
about smoking 
from time to 
time.” 
Provide solutions 
to specific relapse 
triggers 
“How can you deal 
with your desire to 
smoke in those 
situations?” 
Maintenance “I used to smoke.” Solidify patient's 
commitment to a 
smoke-free life 
“This would be a 
good time to share 
your experience 
with other people.” 
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 The goal of counselling patients is to assess their previous attempts tom 
quit and identify what have worked and take actions accordingly. 
 
Chronic Obstructive pulmonary disease (COPD): 
 COPD is characterised by a preventable and treatable disease associated 
with airflow limitation that is not fully reversible 22. This progressive airflow 
limitation is due to the noxious effects of smoke that damages the fragile 
environment of the lungs. The loss of lung function is addressed in terms of 
narrowing of airways, lung parenchymal destruction which leads to compliance 
and elasticity defects and vascular bed damages characterised by increased 
pressures.COPD was ranked 6th commonest cause of death in 1990 by the 
global burden of disease studies.  
 It is projected to become the 3rd cause by 2020 and 5th most common 
cause of chronic disability by 2020 (23).Estimates from WHO suggest that 
90% of COPD related deaths occur in low and middle-income countries with 
India and China mounting to 66% of global COPD mortality(24).COPD along 
with asthma and respiratory illness is the second leading cause of death among 
the population aged 25-69 years in India 25. The prevalence of COPD is on 
rising and expenditure associated with its treatment is more than other common 
respiratory ailments. The global increase in COPD is due to continuous 
cigarette smoking, the longer survival rate particularly in developing nation 
like ours. There has been a touch of neglect in addressing the problem of 
COPD at the global level by the doctors, researchers and the pharmaceutical 
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companies because the underlying disease process is irreversible. Current 
treatment modalities treat the exacerbation associated with COPD the disease 
per se. The need for concrete COPD treatment underlies the fact that many are 
affected due to environmental factors. Indeed 10% of non-smokers and many 
among women with biomass exposure have COPD.COPD with non-smoking 
causes needs more attention. Developing countries have a much higher burden 
with non-smoking causes of COPD than the developed world. Hence more 
detailed research in terms of the molecular and cellular level is needed to curb 
this epidemic of COPD globally.  
 Epidemiological studies have shown that death from COPD is due to an 
accelerated decline in lung function test. There is 50-100 ml of loss in FEV1 
every year compared to less than 30 ml in normal individuals. According to 
studies done by Celli et al., other factors like exercise capacity, exacerbation 
frequency, and associated systemic illness may indicate poor prognosis 26. 
Treatment modalities start with smoking cessation. Unfortunately, abstinence 
from smoking cigarettes has a poor success rate as the quitting rate is around 
15% and several studies have shown smoking cessation fail to reverse 
inflammatory changes in patients. Bronchodilator therapy is the mainstay of 
therapy but with little benefit in the long-term course. 
Magnitude of COPD and its economic burden in India: 
 According to ICMR-PHFI-IHME 2017 data, COPD is the second 
biggest cause of death in India among Non-communicable diseases 27. It is the 
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4th leading cause of years of life lost in Empowered Action Group (EAG) 
states. COPD ranked 7th in North-Eastern states and 4th in other states among 
all causes of years of life lost. COPD and its exacerbation require frequent 
hospitalisation which sometimes needs costly intervention putting the burden 
on the existing resource-limited health care in our country. Elderly people, 
more than 65 years are admitted at a rate 4 times higher than younger ones with 
a mean length of hospital stay ranging from 4 to 16 days. Social structure in 
India limits the utilisation of health care by the elderly at their will and this 
adds to their misery of with COPD. Strategies tackling at early intervention 
with solid scientific background supporting smoking cessation will play a 
major role in healthy society. 
How to tackle COPD problem: 
 To increase awareness among the healthcare individuals, public and 
government organisations. To educate general practitioners to recognise COPD 
early and institute therapy at the earliest. To stop smoking as early as possible 
in patients with the early disease has clear benefits. The attitude that self-
induced smoking habit is creating such a health issue and hence it needs less 
emphasis has to be changed. Tobacco use and biomass smoking in households 
need to be curtailed. 
 There should be better intervention and supportive care at the primary 
health center level to minimise the logistic difficulties in obtaining expert 
views. Everyone in the healthcare system should gain sufficient knowledge in 
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attending to patients with COPD in terms of early diagnosis. To impart 
avoidance of risk factors and routine monitoring during follow up to assess the 
dependence will motivate patients to lead a healthy lifestyle. This is 
particularly important among smokers with COPD. India with its diverse 
culture and regional background smoking cessation is a serious challenge with 
the high-cost delivery of cure. At every District level, separate emphasis on 
treatment in view of emergency intensive care units with all life-saving 
equipment in adequate numbers to all needy COPD patients will alleviate the 
mortality rate and quicker recovery time. 
 With time and then we have been successful in health-related schemes 
and adding up COPD to TB control and other important national programmes 
will be of significance. 
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Pulmonary Function tests (PFT): 
 It is a valuable investigation in the management of respiratory illness. 
But its use in routine clinical setting is subject to question.PFT aid in diagnosis, 
treatment and its response. Basic respiratory physiology is the cornerstone in 
understanding the pulmonary function test and its interpretation. These tests 
indirectly give information on large and small airways, the parenchyma, and 
the integrity of the vascular bed. They do not provide concrete diagnosis per se 
but provide pattern on various abnormalities. European Respiratory and 
American Thoracic Societies have provided guidelines on performing PFTs 2. 
It is effort dependent and hence full cooperation the patient is necessary. 
Indications for performing Pulmonary function tests: 
Investigation of patient with symptoms/signs/investigations that suggest 
pulmonary disease: 
•  Cough 
• Wheeze 
• Breathlessness 
• Crackles 
• Abdominal chest X-ray 
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Patients with pulmonary disease; monitoring and response to treatment; 
progression of the disease: 
• Interstitial fibrosis 
• COPD 
• Asthma 
• Pulmonary Vascular disease 
Investigation of patients with disease that may have a respiratory 
complication: 
• Connective tissue disorders 
• Neuromuscular diseases 
Preoperative evaluation prior to  
• Lung resection 
• Abdominal surgery 
• Cardiothoracic surgery 
Evaluation of patients at risk of lung diseases: 
• Exposure to pulmonary toxins such as radiation  
• Medications with pulmonary side effects 
• Environmental or occupational exposure 
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Contraindications for Performing PFTs 28: 
• Myocardial infarction within last month 
• Unstable angina 
• Recent Thoraco-abdominal surgery 
• Recent Ophthalmic surgery 
• Thoracic or abdominal surgery 
• Current pneumothorax  
• Thoracic aneurysms  
 Patients with active respiratory infection are deferred from performing 
investigation until risk of cross contamination is negligible. Sitting position is 
typically used to prevent risk of falling and injury in the event of syncopal 
episode. 
 Patients are not advised to smoke for at least 1 hour before the 
procedure, not to eat large meals 2 hours before their procedure and not to wear 
tight fitting clothes as these factors may influence the test findings. 
 False teeth are left in place unless the prevent the patient from forming 
an effective seal around the mouth piece. 
 Normal or predicted values from large population studies are taken and 
values are taken for people matched for height, sex, age and in some cases 
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ethnicity. Test should be performed three times to ensure that the results are 
constantly reproducible with less than 200 ml variation. Dynamic studies are 
performed first and other aspects of PFTs are taken subsequently. 
Spirometry 
 Spirometry is used measure lung function. Simple and quick if done 
with full cooperation of the patient. Patients are asked to take maximal 
respiration and then to expire forcefully. 
 
 
 
 
 
 
Fig-Normal Spirometry 
Measurements made by spirometer: 
• Forced expiratory volume in one second (FEV1). 
• Forced vital capacity. 
• The ratio of the two volumes (FEV1/FVC) 
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Spirometric Values: 
1. FVC - Forced vital capacity; the total volume of air that can be exhaled 
during a maximal forced expiration effort. 
2. FEV1 - Forced expiratory volume in one second; the volume of air exhaled 
in the first second under force after a maximal inhalation. 
3. FEV1/ FVC ratio—The percentage of the FVC expired in one second. 
4. FEV6 - Forced expiratory Volume in 6 seconds 
5. FEF 25-75% - Forced expiratory flow over the middle one half of the 
FVC. 
The range at which 25 percent to 75 percent of air is exhaled. 
6. MVV - Maximal voluntary Ventilation. 
Lung Volumes: 
1. ERV - Expiratory reserve volume; the maximal volume of air exhaled from 
end-expiration. 
2. IRV - Inspiratory reserve volume; the maximal volume of air inhaled from 
end-inspiration. 
3. RV - Residual volume  
4. VT - Tidal volume 
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Lung Capacities: 
1. FRC - Functional residual capacity; the volume of air in the lungs at 
resting end-expiration. 
2. IC - Inspiratory capacity; the maximal volume of air that can be inhaled 
from the resting expiratory level. 
3. TLC - Total lung capacity; the volume of air in the lungs at maximal 
inflation. 
4. VC - Vital capacity; the largest volume measured on complete exhalation 
after full inspiration. 
 
 The basic idea of spirometry is top measure the changes in lung volumes 
during forced expiratory and inspiratory manoeuvres. It begins by asking the 
patient to undergo full inspiration and asked tom rapidly exhale the air. This 
exhalation is asked to prolong as much as possible. This effort is recorded, and 
it is computerised for better viewing of the curves and the final results. The 
total lung capacity is calculated with the addition of the main 4 volumes 
   1. ERV - expiratory reserve volume 
    2. IRV - inspiratory reserve volume 
    3. RV - residual volume  
    4. TV - tidal volume 
 The most important spirometric value is the FVC and the manoeuvre 
done for its measurement is most crucial in the process. During rapid 
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exhalation lung tends to exhale 80% of the air within the first 6 seconds or less. 
FEV1 is the Forced expiratory volume in the first second of FVC.  
FEV1/FVC is an important parameter extrapolated in this setting. 
Normal Values of Pulmonary function tests: 
Pulmonary function tests Normal values 
FEV 1  80-120% 
FVC  80-120% 
Absolute FEV1/FVC Within 5% of the 
predicted ratio 
 
TLC  80-120% 
RV  75-120% 
DLCO >60% to <120% 
 
 The ratio primarily helps in the identification of an obstructive or 
restrictive pattern of disease. When FEV1 is reduced more than FVC it 
signifies obstructive pattern of pathology (ratio < 70%). Examples include 
Obstructive defects like chronic obstructive pulmonary disease and asthma. 
The ratio can further classify the degree of obstruction. The ratio of FEV1/FVC 
>70% with FVC reduced more than FEV1 suggests a restrictive pattern of 
diseases such as interstitial lung disease and chest wall deformities. 
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FEV1 % predicted Stage  
> 80% Mild 
50-79% Moderate 
30-49% Severe 
<30% Very Severe 
 
Table: Severity of airflow obstruction based on percentage predicted 
FEV1. 
 The most disease patterns fall into these categories. This is calibrated to 
the population pattern and subjected to a standard set by the international 
organization. Every value is comparable with age, sex, and other physical 
variables. 
Interpreting spirometry results: 
Determine whether the test results are interpretable. 
Assess the FVC, FEV1 and absolute FEV1/FVC ratio. 
1.  Normal Spirometry - FVC normal; FEV1 normal; and absolute 
FEV1/FVC > 0.7 
2.  FVC decreased; FEV1 decreased or normal; absolute FEV1/FVC >0.7 
     Suggests Restrictive ventilatory impairment 
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     Further referral to pulmonary laboratory for static ling volumes DLCO, 
ERV and check for MVV. 
3.  FVC normal or decreased; FEV1 decreased; Absolute FEV1/FVC < 0.7     
suggests obstructive ventilatory pattern. Then bronchodilator challenge 
test.  
 Here in this test, a 12 percent increase in FEV1 and increase in FVC or 
FEV1at around 200 ml suggests a reversible airway disease., 
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Algorithm for interpreting results of spirometry. 
 At least 3 acceptable spirographs must be obtained for the validity of the 
spirometric results. The test session is finished when the difference between 
largest FVC measurements and between two largest FEV measurements within 
the 0.2 liters .8 attempts are performed to meet the above criteria. 
 When the test is said to be valid, the second step is to determine whether 
an obstructive or restrictive pattern is noted. 
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When the FVC and FEV1 are decreased, the absolute FEV1/FVC ratio helps us 
to differentiate between obstructive and restrictive pattern. FEV1/FVC is 
normal or increased it is a restrictive pattern. Then the patient is referred to the 
Pulmonary laboratory for static lung volumes. If Total lung capacity is less 
than 80%, it is a restrictive pattern. 
 In this case diseases like pneumonia, pleural effusion, pulmonary 
fibrosis, and congestive heart failure are taken into consideration. 
 The obstructive pattern is recognized by the reduced FEV1 and 
FEV1/FVC ratio. 
 Bronchodilator challenge test is recommended to detect patients with 
reversible airway obstruction like asthma. The patient should not have used 
bronchodilator for at least 48 hours before the test is performed. In this 
bronchodilator challenge test, a bronchodilator is given, and spirometry is 
repeated after some time. A positive test is implied by an increase in FEV1 by 
12% and FVC increased by 200mL. 
 Mid-expiratory flow rate (25-75%) is the average forced flow rate over 
the middle 50% of the FVC. This helps in the diagnosis of the obstructive 
pattern. Under a strong clinical suspicion, a reduction in MEF 25-75% of less 
than 60% and FEV1/FVC reduced may confirm airway obstruction. 
 Maximal voluntary ventilation maneuver is done to confirm restrictive 
and obstructive patterns. The participant is asked to breathe as hard as possible 
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for 12 seconds. The results are further interpreted for 60 seconds and reported 
in liters per minute. 
 MVV is approximately 40 times FEV1. A low MVV can occur in 
obstructive disease but more common in case of a restrictive pattern. When 
MV is low and other parameters like FEV1 and FVC are normal suggests poor 
patient effort, major airway lesion or neuromuscular defect.  
 MEF 25-75 represents the forced expiratory flow between 25% and 75% 
of Vital capacity and reflects the small airway patency. Smoking leads to a 
particular decline in the lung function. The obstruction in the airflow is 
primarily due to the abnormalities in the airways less than 2mm in internal 
diameter. 
 Chronic inflammation of membranous and respiratory of bronchioles. 
The smokers have fewer PFT values in all the parameters compared to non-
smokers. 
 Younger smokers have lesser values compared to elderly smokers. The 
reduction in MEF 25-75 among smokers were significantly lower due to the 
involvement of the smaller airways. With salbutamol challenge of around 200 
mcg, there was some reversibility noted in smokers. This proves that smaller 
airways are more susceptible to airway reversibility to salbutamol and smoking 
cessation. 
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Normal Flow volume loop: 
The normal Spirometric flow diagram. 
A- Flow volume curve  
B - Volume-time curve. 
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The smooth lines, expiratory time of greater than 6 seconds, and quick peak of 
expiratory flow rate is a good spirometric effort. 
Flow volume curve in Obstructive lung disease: 
 
 
53
Flow volume curve in Restrictive lung disease: 
 
Flow volume curve in Intra-thoracic airway obstruction: 
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 PFTs take 15 minutes for adults,15-30 minutes for children,45 minutes 
for Pre and post bronchodilator testing. 
 Within the manoeuvre criteria for reproducibility and acceptability 
following things are considered: 
 Individual spirograph are acceptable if 
1. They are free from artefacts 
• Cough during the first second of exhalation 
• Glottis closure that influences the measurement 
• Early termination or cut off  
• Leak 
• Obstructed mouthpiece 
2. They have good starts 
• Extrapolated volume <5% of FVC or 0.15 liters, whichever is greater 
3. They have satisfactory exhalation 
• Duration of > 6 seconds (>3 seconds for children) or a plateau in the 
volume - time curve or if subject cannot or should not continue to 
exhale. 
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Between manoeuvre criteria: 
1. After three acceptable spirograph have been obtained, apply the following 
tests  
• The two largest values of FVC must be within 0.150 liters of each other 
• The two largest values of FEV1 must be within 0.150 liters of each other 
2. If both of these criteria are met test session may be concluded. 
3. Total of eight tests can be performed. 
 The technical difficulties in conducting these tests can be alleviated by 
proper education of the patients regarding the procedure. This helps the patient 
ti psychologically handle the stress in doing the procedure. 
 Lot of effort is needed in educating the patients about the procedure and 
skillful assistants are important in this process. 
 The proper ambience and quiet place are important in the analysis of the 
spirometry. 
 Best results are obtained from best support team and very good 
ambience. The best possible results help in unmasking the COPD in early 
stages. 
 Multitude of parameters are considered, and all are resulted in 
computerised manner to get the better results. 
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Volume Daily Calibration check with a 
3-litre syringe 
Leak Daily 3 cmH20 (0.3 kPa) 
constant pressure for 1 
min 
Volume Linearity Quarterly 1-litre increments with a 
calibrating syringe 
measured over entire 
volume range 
Flow linearity Weekly Test at least 3 different 
flow ranges 
Time  Quarterly Mechanical recorder 
check with stopwatch 
Software New versions  Log installation date and 
perform test using 
“known” subject. 
 
 These tests are done ensure the proper results and hence correlates with 
the diagnosis through this tedious spirometry procedure 
 A study done by Zhang et al compared clinical features between non-
smokers with COPD and smokers with COPD 29. They concluded Non-
smokers had less impairment of airflow and gas exchange. There was a lesser 
prevalence of emphysema, chronic cough, and sputum among non-smokers 
compared with smokers. Comorbidities including hypertension, diabetes and 
coronary heart disease were not significantly different between the two groups 
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in the study. Patients with COPD are at increased risk of developing 
Myocardial infarction, angina, osteoporosis, bone fractures, depression, 
respiratory infections, and diabetes. It may contribute to these comorbidities 
through its extrapulmonary effects such as malnutrition and skeletal muscle 
dysfunction. Tobacco causes goblet cell hyperplasia and chronic hypersecretion 
of mucus and it is evident by the results from the study showing more chronic 
cough and phlegm among smokers than non-smokers. The extracellular matrix 
destruction in terms of poorer diffusion capacity on lung function test and more 
emphysema on X-ray is seen more often with smokers. 
 Asthma, congestive heart failure, congestive heart failure, tuberculosis, 
diffuse pan bronchiolitis, bronchiolitis are mentioned as the differential 
diagnosis for COPD in GOLD criteria. Spirometry is essential for the diagnosis 
of COPD and its confirmation. Some tools are developed for screenings 
spirometry has its disadvantages in terms of cost and logistics. Hence 
questionnaire was developed to identify patients at risk of developing COPD. 
 Lung function questionnaire (LFQ) items were identified during the 
empirical phase (version 1) and the revised lung function questionnaire 
(Version 2) from physician and patient inputs. 
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Version 1 Version 2 
Do you currently smoke? Do you frequently cough up mucus? 
How many years have you 
smoked? 
Does your chest often sound noisy (wheezy, 
whistling) when you breathe? 
When smoking, about how 
many cigarettes were or are 
typically smoked each day? 
Do you experience shortness of breath upon 
physical exertion (walking up a flight of stairs 
or walking up an incline without stopping to 
rest)? 
Troubled by shortness of breath 
when hurrying on level ground 
or walking up a slight uphill? 
What is your age range? 
When you develop cold, does 
your respiration sound wheezy 
or noisy? 
How many years have you smoked? 
Do you cough out sputum for 
days for 3 consecutive months 
or more during a year? 
When smoking, about how many cigarettes 
were or are typically smoked each day? 
What is your age range? Do you currently smoke? 
 
 As spirometry is not practical in all settings. Hence these set of items 
identifies patients with spirometry-based obstruction and for potential inclusion 
in the LFQ. 
These parameters include  
1.  Age 
2. Occurrence of wheezing 
3. Phlegm 
4. Dyspnea 
5. Smoking history. 
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 This LFQ can be used in primary care settings as a screening tool and 
identify the patients at earliest to identify patients with obstruction. This LFQ 
has adequate accuracy, sensitivity, and specificity. 
 An 11-questionnaire was developed to grade COPD and it includes 
qualitative and quantitative analysis of the patient. Among the 11 questions, 
five are related to respiratory symptoms. Others include patient background 
and other details related to COPD. General symptoms like fatigue, insomnia, 
irritability, and anxiety were not included as these may interfere with other 
disease processes too. 
 This test is particularly helpful in elderly and it correlates with dyspnea 
and palpitation more with COPD than ischemic heart disease. It is less time 
consuming as it takes less than 5 minutes to complete and easy at the level of 
primary care settings. Scoring systems of the 11 items on the Questionnaire for 
the efficient screening of COPD: 
1.   Average number of cigarettes per day, then multiply by your smoking 
duration in years. 
0: less than 200 
1: 201-400 
2:  401-600 
3: 601-800 
4: 801-1000 
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 5: 1001-1200 
 6: 1201-1600 
 7: over 1601 
2.   How old are you? 
           0: under 50 
           1: 50-59 
           2: 60-69 
           3: 70-79 
           4: over 80 
3. Do you experience sputum (phlegm) or coughing every day? 
                     0: not at all 
                     1: Small amounts of sputum or coughing during the day 
                     2: moderate amounts of sputum or coughing during the day 
                     3: Large amounts of sputum or coughing during the day 
4. Do you experience episodic wheezing? 
                       0: Not at all 
                       1: seasonally 
                       2: When climbing stairs or slopes 
                       3: When changing clothes 
                       4: Frequently during the day 
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5. Do you experience dyspnea on exertion? 
                       0: No dyspnea when climbing a flight of stairs, while carrying       
       baggage. 
                      1: Feel dyspnea at the top of a flight of stairs, while carrying 
baggage. 
                      2: No dyspnea until the top of a flight of stairs, without any rest. 
                       3: Require a rest when climbing a flight of stairs. 
                       4: Require two or more rests before the top of a flight of stairs. 
                       5: Unable to climb a flight of stairs in any case. 
6. Do you experience any palpitations (rapid heart rate). 
                     0: Not at all 
                     1: when climbing up slopes or stairs 
                     2: When walking on flat surfaces 
                     3: Always. 
7. Is your sleep ever disturbed by episodic dyspnea? 
                   0: not at all 
                   1: Once a month  
                   2: Occasionally 
                   3: Frequently 
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8.  Did you suffer from occasional common colds, asthma attacks or 
pneumonia in your childhood? 
                  0: No 
                  1: Yes 
9.  Have your parents or siblings experienced asthma attacks or complained 
of dyspnea? 
                    0: No 
                  1: Yes 
10.  Are you exposed to dust or heavy traffic in your home or working 
environment? 
                   0: No 
                    1: Yes 
11.  Are you excessive underweight or overweight? 
                   0: No 
                    1: Yes 
 This questionnaire further enhances the physician and patient 
participation in the nicotine addiction and helps in smoking cessation. 
 Lung function decline in COPD was done by landmark study of Fletcher 
and Peto31on the natural history of tobacco smoke-related chronic airflow 
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obstruction. There is a decline in the forced expiratory volume in the first 
second (FEV1) in the COPD. The decline in the FEV1 slow in the beginning 
and begins faster with a more advanced disease. The mean rate of decline in 
GOLD stages II and III is between 47 and 79 ml/year and 56 and 59 ml/year 
respectively. This decline his lower than 35 ml/year in stage IV. Every 6 
months for an 8-year follow up period well-known graph was obtained and let 
to the understanding of the COPD pathologic process. 
Information obtained from Fletcher and Peto work are: 
• Individuals susceptibility to smoking-related lung damage 
• The progression of the airflow obstruction once COPD is diagnosed. 
• Variability in abnormal lung function and its decline among patients. 
• Reduction of excessive FEV1 decline after smoking cessation at all 
times. 
• A rarity of self-reported symptoms when airflow reduction is mild to 
moderate. 
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Modified Fletcher and Peto’s Graph 
 This Modified curve of Fletcher and Peto suggested smoking cessation 
at an earlier age is more beneficial than at later stage in regard to retardation of 
obstructive changes. Likewise, cessation of smoking before 40 years is more 
beneficial than later.Any intervention done after 50 percent of lung loss is not 
fruitful is patients’ symptomatic relief and projects a bad prognosis. 
Limitations of Fletcher and peto’s curve are 
1.  All subjects were males 
2.  Age of recruitment was between 30 and 59 
3.  Follow up period was short compared with the large time range 
shown on the X-axis of the graph. 
4.  Curves were extrapolated backward and forward with inaccuracies 
leading to distorted inference. 
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5.  These findings suggest major therapeutic efforts at the level of severe to 
very severe obstruction in COPD. 
 These limitations were further supported by large amounts of data 
collected to challenge this hypothesis on the basis of Fletcher and Peto’s curve. 
 In a study conducted by Dawkins et al showed an interesting data on the 
decline in lung function in patients with alpha 1 antitrypsin deficiency-related 
emphysema in terms with GOLD criteria 32. In patients with PiZ phenotype, the 
mean annual decline in FEV 1 was correspondingly higher when compared 
with general COPD patients. 
 Rate of annual decline of the forced expiratory volume in the first 
second (FEV1) in Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) stage I–IV chronic obstructive pulmonary disease patients with alpha-
1-antitrypsin deficiency-related emphysema measured during a longitudinal 
study with a 3-year follow-up period: 
GOLD stage No of 
patients 
Age range (yr) Mean FEV1 decline 
(mL/yr) 
I 18 49 ± 9 32 ± 19 
II 26 51 ± 9 90 ± 19 
III 38 53 ± 11 52 ± 8 
IV 19 49 ± 9 8 ± 9 
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 Similar cohort studies were done and provided data in lung function 
decline in COPD patients. 
Reference Study GOLD 
stage 
Patients 
(n) 
Age range 
(yr) 
Follow-
up 
period 
(yr) 
Mean 
FEV1 decline 
(mL/yr) 
Bridevaux et 
al 
SAPALDIA 1 I 430 18–60 11 40 ± 37 
Vestbo et al CCHS I–II 145 59 ± 10 3 42 
Anthonisen 
et al 
LHS II 1964 35–60 5 56 
Pauwels et al EUROSCOP II 643 30–65 3 69 
Anthonisen 
et al 
LHS-3 II 1357 30–60 11 53 
LHS 
Research 
Group 
LHS-2 II 557 40–69 3 47 
Jenkins et al TORCH II 535 40–80 3 60 
Lapperre et 
al 
GLUCOLD II 24 45–75 3 79 
Decramer et 
al 
UPLIFT II 1355 64 ± 9 4 49 
Burge et al ISOLDE III 375 40–75 3 59 
Jenkins et al TORCH III 775 40–80 3 56 
Decramer et 
al 
UPLIFT III 1331 65 ± 8 4 38 
Jenkins et al TORCH IV 214 40–80 3 34 
Decramer et 
al 
UPLIFT IV 271 63 ± 8 4 23†† 
 
 
 
68
 According to the evidence provided the acceleration of lung function 
was more so in the early stages and hence early intervention is much better than 
at later stages with anatomical damage. 
 Hence, a different curve pattern in the decline of lung function was 
elucidated which contradicts the view of Fletcher and Peto’s curve. 
 This trend is explained by the more loss in early stages of COPD than at 
later stages. This FEV1 loss can be partly compensated by the increase in total 
lung capacity in GOLD stage IV COPD patients. Some studies have shown that 
FEV1 is poorly related to symptoms and even to exacerbations. Therefore, a 
greater loss of lung function during the early stages of disease holds good.   
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Comparison of Fletcher and Peto’s curve with newer envisaged Curve 
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MATERIALS AND METHOD 
     Study design:-  observational study 
     Study period:- 6 months 
     Study area:- GOVT KILPAUK MEDICAL COLLEGE 
     Study population: 
     Males among age group18-50 years are recruited. 
     Study population includes both smokers and non smokers 
      The subjects selected for present study will be recruited from medical 
outpatient Department at our hospital. 
SAMPLE SIZE:- 
                             Smokers   :75 
 
                   Non smokers :75 
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INCLUSION CRITERIA: 
 The random sample of smokers and non smokers will be selected who 
fulfill the following criteria 
NON SMOKERS: 
 Person who  does not smoke tobacco 
 Person not dwelling in the home where their spouse or other family 
members are smokers of hookah,cigarette,cigar or beedi. 
 (In other words they were not passive smokers. A passive smoker refers 
to exposure to  tobacco consumption products from smoking of others) 
SMOKERS: 
 They are persons who are engaged in the inhalation and  exhalation of 
fumes of burning tobacco in cigarettes. 
 By definition, cigarette smokers are the persons who inhale, exhale and 
burn or carry any lightened cigarette. (the person who smokes atleast 5 
cigarettes per day for 10 years)  
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EXCLUSION CRITERIA: 
 
 The following groups of persons will not be included in the study. 
1. Females 
2. Known case of BA,COPD,TB,ILD 
3. The person who are morbid or have full fledged picture of cor 
pulmonale on clinical examination. 
4. The person who work in textile mills or other places where lungs 
are affected by dust or  fumes. 
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METHODOLOGY 
 
• Each person who fulfill the inclusion criteria will be included in 
the study. 
• Clinical history to be taken. More emphasis to be made on 
occupational history. 
• Enquiry on smoking habits. Duration and the average number of 
cigarettes per day. 
• All the tests will be done between 10.00 to 17.00 hours to avoid 
possible diurnal variation. 
• Each person will be allow to take  rest for about two minutes 
before the actual test. 
• The details of the test will be explain and demonstrate to each of 
them by myself or by operator. 
• The person has to be asked to take deep inspiration from outside 
and then to expire as  forcefully and as fast as he can inside the 
mouthpiece.  
• Expiratory flow volume curves will be recorded by spirometer 
• The value of Mid Expiratory Flow Rate will be obtained from the 
graph. The data of each patient will be collected in specific 
proforma (ANNEXURE 2) which includes patient’s name, age, 
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sex, demographic details, presenting complaints, risk factors and 
all clinical data.  
• All the relevant data and values are then entered in master chart 
in Microsoft excel format an then analyzed statiscially. 
 
 
 
 
 
 
 
  
 
75
STATISTICAL ANALYSIS  
Statistical Analysis 
 The data was collectedin the master chart obtained in the Microsoft 
excel format. 
 The collected data were analysed with IBM.SPSS statistics software 
23.0 version. To describe the data descriptive statistics frequency analysis, 
percentage analysis was used for categorical variables and the mean and 
Standard deviation was used for continuous variables. To find the significant 
difference between the bivariate samples in Independent groups the unpaired 
sample t-test was used. For the multivariate analysis, the KrusalWalli’s was 
used. In both the above statistical tools the probability value 0.05 is considered 
as significant level. 
 
 
 
 
 
 
 
 
 
76
Results: 
 The results of test conducted among 75 participants who smokers and 
equal number of participants without smoking history. Age group with 
maximum distribution was among 41-50 years of age (N=64 ;42.7%). All 
participants selected were under 50 years to exclude inert conditions like 
IHD,Systemic hypertension with the interpretation of results. Duration of 
cigarette smoking was maximum at 11-20 years of smoking which more or less 
applies to majority of population in society. 
Descriptive statistics: 
Descriptive analysis among smokers have shown following details: 
 N Minimum Maximum Mean Std. Deviation 
CIGARETTES 
PER DAY 75 10.0 25.0 17.880 3.4834
DURATION 75 10.0 35.0 20.440 6.0855
PACK 
YEARS 75 7.5 30.0 18.125 5.9711
Valid N 
(listwise) 75     
 
 The mean cigarettes smoked per day was around 18 among participants. 
 Mean duration was 20 years which extrapolates to the general 
population at large.  
 Pack years amounts to 18 which leads to susceptible population.  
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Description of MEF among smokers with cigarettes per day: 
Cigarettes N Mean Std. Deviation Minimum Maximum 
1 - 10  2 59.00 0.000 59 59 
11 - 20  64 42.39 8.664 26 60 
21 - 30  9 35.67 5.148 27 43 
Total 75 42.03 8.922 26 60 
 
Among participants with smoking history MEF 25-75%; 1-10 cigarettes per 
day of smoking with 2 members with mean of 59 in MEF 25-75%. 
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Test Statistics (a,b) 
  MEF 25-75 
Chi-Square 10.762
df 2
Asymp. Sig. .005
a. Kruskal Wallis Test 
b. Grouping Variable: Cigarettes per day 
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DISCUSSION 
 The Mid-expiratory flow rate (MEFR) causes obstruction of airways 
more commonly the smaller airways. Likewise in our study, the obstruction of 
smaller airways is projected by a decrease in MEFR among smokers. The more 
alarming trend in the increase in the smoking among the adolescents 11 within 
communities has been projected in our study. Up to 20 years, our participants 
were around 3.3%; 21-30 years 20.7 % were included in our group. More 
participants were included 11-20 years of duration of smoking which was 
around 60 percent of the study group among smokers. 
 Next comes is 21-30 years of smoking which was around 37.3 percent. 
 Most of the studies conducted have a similar trend of the smoking 
pattern. The similar trend is due to the addiction pattern seen in the individuals 
among societies. 
 Next important pattern seen is the cigarettes per day wherein the similar 
fashion is seen. Here the number of cigarettes ie 11-20 per day is 85.3% is 
among the participants. The next group is smoking around 21-30 cigarettes per 
day is around 12%. The least which is 1-10 of cigarettes per day is 2.7 percent. 
 This creates a unique combination of an increasing number of cigarettes 
and the duration of cigarettes. More the duration increases the number of 
cigarettes. The MEFR was drastically reduced with more the duration and more 
the number of cigarettes smoked. According to GATS 2 the tobacco users by 
age group was around 12.4% in 15-24 years; 30.1% in 25-44 years; 39.9% in 
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45-64 years and 41.4% in 65 plus age group. This similar trend was noticed 
with an increase in smoking in the middle age group of people. In Tamil Nadu, 
the overall prevalence was around 5.2%with males around 4.3% and females 
0.9 %. 
 The important point to note is that the smoking issues among rural and 
urban areas in narrowed with the rising awareness and reachability of tobacco 
products to nook and corner of the country. Tobacco use was around 2.5% in 
urban compared to 2.6% in rural areas. According to the Government data, 27  
COPD is ranking 7th in Northeastern states and 4th in rest of the states, telling 
the penetrance of tobacco on a widespread level. 
 The important parameter into consideration in the evaluation of smokers 
is the development of the obstructive pattern noted in the smaller airways. 
 MEFR 25-75% was less than 50 in around 81 percent of smokers 
implying the nature of burden in the smaller airways in asymptomatic smokers. 
This alarming reduction in the MEFR among smokers that too in asymptomatic 
participants urges the physician to screen all patients with smoking history to 
undergo rigorous psychological procedures to curtail its use. 
 As shown in our study the number of cigarettes and duration are 
synonyms which explains the basis of involvement of reward centers and other 
addiction centers in the brain. 
 This was well supported in our study wherein the Non-smokers had a 
MEFR 25-75% mean of 100 compared to 42.0 which is a significant reduction 
in the MEFR in terms of diagnosis and the natural course of the disease. 
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 The trend in Fletcher and Peto ’s curve was supported; more reduction 
in the flow rate with increase in the duration of smoking. 
 In our study, 1-10 years of smoking was accounting to a MEFR mean  
of 57  
 And a further decline in the subsequent study group among smokers. 
 11 – 20 years of smoking had a MEFR mean of 45.71which is a 
significant decline  
 And more than 20 years smoking amounting to a mean of 35. 
 This supports Fletcher and Peto’s hypothesis. 
 But the drastic drop in the MEFR in smokers with less duration of 
smoking as compared with non-smokers in our group has challenged the 
Fletcher and Peto’s results stating decline in pulmonary function in terms of 
spirometric values goes hand in hand with duration. 
 The proportion of reduction in more with early smokers than with 
chronic smokers over 20 years. 
 Various studies support our results wherein in the reduction of flow 
rates in particularly MEFR is more in early stages than in the late stages. 
 This urges the physician at a community level to curb the menace of 
smoking at the earliest. 
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CONCLUSION 
 Mid Expiratory flow rate 25-75% is reduced in chronic smokers. 
 The rate of reduction in MEFR 25-75% is earlier among asymptomatic 
smokers than non smokers 
 This is contrary to the popular belief that longer the duration of smoking 
there is an increased  rate of reduction of MEFR 25-75% 
 The MEFR 25-75 % is normal in the non-smoker group – irrespective of 
the age distribution. 
 The reduction in MEFR25-75% is directly proportional to the duration 
as well as quantum of smoking. 
 Hence decreasing the quantum of smoking as well as early cessation of 
smoking prevents COPD. 
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ANNEXURE A  
 PROFORMA 
PROFORMA             
NAME: 
AGE/SEX: 
ADDRESS: 
OCCUPATION: 
IP/OP NO: 
QUESTIONNAIRE: 
            Kuppusamy socio economic state: 
            Smoker/non smoker: 
            Duration of smoking: 
            No of cigarettes per day: 
            Pack years: 
            Passive smoking: 
            Co morbid illnness: SHT/DM/BA/COPD/TB/ILD: 
            Family history of SHT/DM/BA/COPD/TB/ILD: 
            PULMONARY FUNCTION TEST: 
 MID EXPIRATORY FLOW RATE  (25-75): 
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ANNEXURE 2 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
SR.NO AGE SMOKER
    NON 
SMOKER
         
CIGARETTES 
PER DAY
        
DURATION
 PACK 
YEARS
MEF 25-75%
1 48 YES 20 30 30 28%
2 34 YES 97%
3 39 YES 18 15 14 46%
4 48 YES 96%
5 38 YES 20 15 15 44%
6 27 YES 104%
7 35 YES 99%
8 40 YES 20 18 18 43%
9 48 YES 20 15 15 45%
10 22 YES 104%
11 42 YES 15 22 17 45%
12 39 YES 20 14 14 48%
13 24 YES 102%
14 20 YES 119%
15 40 YES 20 25 25 35%
16 25 YES 108%
17 43 YES 16 21 17 42%
18 21 YES 115%
19 31 YES 104%
20 50 YES 15 30 22 34%
21 41 YES 18 15 14 45%
22 45 YES 85%
23 50 YES 16 35 28 26%
24 21 YES 110%
25 43 YES 98%
26 48 YES 20 25 25 34%
27 45 YES 22 20 22 35%
28 30 YES 102%
29 39 YES 96%
30 49 YES 18 20 18 43%
31 44 YES 85%
32 44 YES 15 20 15 44%
33 28 YES 106%
34 30 YES 103%
35 20 YES 116%
36 44 YES 20 20 20 38%
37 39 YES 15 19 14 48%
38 31 YES 106%
39 40 YES 97%
40 48 YES 20 18 18 40%
41 43 YES 20 25 25 34%
42 25 YES 109%
43 23 YES 106%
44 50 YES 20 25 25 35%
45 33 YES 93%
46 50 YES 12 30 18 45%
47 47 YES 12 24 14 49%
48 37 YES 97%
49 25 YES 103%
50 48 YES 15 30 23 34%
51 39 YES 15 18 14 47%
52 31 YES 110%
53 49 YES 15 20 15 44%
54 26 YES 103%
55 34 YES 98%
56 18 YES 116%
57 50 YES 20 30 30 28%
58 43 YES 18 15 14 49%
59 50 YES 24 20 24 35%
60 39 YES 15 13 9.8 53%
61 23 YES 109%
62 48 YES 20 28 28 27%
63 39 YES 93%
64 38 YES 15 10 7.5 58%
65 29 YES 20 10 10 55%
66 30 YES 102%
67 41 YES 15 12 9 55%
68 50 YES 25 20 25 34%
69 42 YES 95%
70 40 YES 89%
71 50 YES 21 16 17 43%
72 36 YES 99%
73 50 YES 15 30 23 33%
74 24 YES 103%
75 49 YES 96%
76 47 YES 15 25 19 40%
77 20 YES 114%
78 49 YES 25 24 30 27%
79 32 YES 93%
80 39 YES 15 15 11 54%
81 28 YES 106%
82 45 YES 20 15 15 45%
83 33 YES 94%
84 29 YES 103%
85 49 YES 24 20 24 33%
86 41 YES 16 21 17 42%
87 42 YES 87%
88 39 YES 20 15 15 44%
89 22 YES 110%
90 49 YES 15 25 19 41%
91 34 YES 101%
92 26 YES 108%
93 48 YES 24 15 18 40%
94 50 YES 20 30 30 29%
95 46 YES 94%
96 39 YES 20 12 12 51%
97 35 YES 101%
98 47 YES 15 30 23 32%
99 49 YES 20 20 20 39%
100 47 YES 84%
101 37 YES 97%
102 29 YES 105%
103 47 YES 20 27 27 30%
104 26 YES 105%
105 43 YES 20 20 20 37%
106 23 YES 109%
107 39 YES 16 12 9.6 58%
108 42 YES 85%
109 48 YES 15 28 21 35%
110 40 YES 93%
111 45 YES 24 15 18 42%
112 25 YES 108%
113 39 YES 14 19 13 50%
114 28 YES 102%
115 38 YES 96%
116 42 YES 20 22 22 35%
117 43 YES 14 23 16 46%
118 33 YES 101%
119 34 YES 18 14 13 54%
120 39 YES 20 15 15 46%
121 27 YES 109%
122 36 YES 15 12 9 60%
123 35 YES 93%
124 38 YES 10 18 9 59%
125 49 YES 16 35 28 29%
126 43 YES 97%
127 36 YES 15 16 12 53%
128 44 YES 20 13 13 45%
129 21 YES 108%
130 50 YES 20 25 25 33%
131 35 YES 20 15 15 46%
132 32 YES 96%
133 48 YES 20 20 20 38%
134 19 YES 105%
135 41 YES 98%
136 48 YES 15 30 22 34%
137 44 YES 14 20 14 48%
138 32 YES 94%
139 38 YES 10 19 9.5 59%
140 24 YES 109%
141 37 YES 99%
142 50 YES 20 20 20 37%
143 41 YES 83%
144 27 YES 106%
145 39 YES 15 15 11 55%
146 43 YES 24 20 24 32%
147 29 YES 101%
148 38 YES 12 20 12 53%
149 36 YES 102%
150 38 YES 95%
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ANNEXURE 3 
PATIENT CONSENT FORM 
• Study detail  : “COMPARATIVE STUDY OF MID EXPIRATORY 
FLOW RATE BY USING SPIROMETRY IN AYMPTOMATIC 
SMOKERS AND NON SMOKERS AS A MARKER OF EARLY 
AIRFLOW OBSTRUCTION” 
 
• Study centre  :  KILPAUK  MEDICAL COLLEGE, CHENNAI 
• Patients Name: 
• Patients Age: 
• Identification Number : 
• Patient may check (     ) these boxes 
• I  confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
• I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
• I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
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information released to third parties or published, unless as required 
under the law. I agree not to restrict   the use of any data or results that 
arise from this study. 
• I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well-being or any unexpected or unusual 
symptoms. 
• I hereby consent to participate in this study. 
• I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 
       Signature/thumb impression:   
       Patients Name and Address:                   place  
 date 
      Signature of investigator:    
 
 
• Study investigator’s Name:                       place   date  
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சுயஒப்புதல் படிவம் 
ஆய்வு ெசய்யப்படும் தைலப்பு:  
இடம்: ெபாது மருத்துவத்துவ துைர  
அரசு  கீழ்பாக்கம் மருத்துவ கல்லூr மருத்துவமைன  
ெசன்ைன    
பங்குெபறுபவrன்  ெபயர் :  
பங்குெபறுபவrன்  வயது :                     
 பங்குெபறுபவrன்  எண் :  
 ேமேல குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவரங்கள் எனக்கு 
விளக்கப்பட்டது.நான் இவ்வாய்வில் தன்னிச்ைசயாக 
பங்ேகற்கிேறன்.எந்த காரணத்தினாேலா எந்த சட்டசிக்கலுக்கும் 
உட்படாமல் நான் இவ்வாய்வில் இருந்து விலகிக்ெகாள்ளல்லாம் 
என்றும் அறிந்து ெகாண்ேடன். 
இந்த ஆய்வு சம்பந்தமாகேவா,  இைத சார்ந்து ேமலும் ஆய்வு 
ேமற்ெகாள்ளும்ேபாதும் இந்த ஆய்வில்பங்கு ெபறும் மருத்துவர் 
என்னுைடய மருத்துவ அறிக்ைககைள பார்ப்பதற்கு என் அனுமதி 
ேதைவயில்ைல என அறிந்து ெகாள்கிேறன்.  இந்த ஆய்வின் மூலம் 
கிைடக்கும் தகவைலேயா, முடிைவேயா பயன்படுத்திக்ெகாள்ள மறுக்க 
மாட்ேடன். 
இந்த ஆய்வில் பங்கு ெகாள்ள ஒப்புக்ெகாள்கிேறன்.   இந்த ஆய்ைவ 
ேமற்ெகாள்ளும் மருத்துவ அணிக்கு உண்ைமயுடன் இருப்ேபன் என்றும் 
உறுதியளிக்கிேறன். 
  
பங்ேகற்பவrன்   ைகெயாப்பம்                ஆய்வாளrன்   ைகெயாப்பம்  
இடம் : 
ேததி : 
 
 
